New ECMM Study

Observational study to determine the rate of occurrence of invasive mould disease and treatment outcomes in at-risk patients: a European prospective invasive mould disease audit (PIMDA).

ECMM is seeking participation from European hospitals with haematology units and/or transplant centres that frequently treat patients for AML/MDS, or recipients of an allogeneic HSCT, or both, to take part in an observational study to determine the rate of occurrence of invasive mould disease (IMD) and treatment outcomes in at-risk patients.

ECMM intends to conduct an observational study to determine the rate of occurrence of invasive mould disease (IMD) and treatment outcomes in at-risk patients. This will be the first study of its kind in IMD, and is funded through an independent investigator research grant from Pfizer.

We are seeking participation from European hospitals with haematology units and/or transplant centres that frequently treat patients for AML/MDS, or recipients of an allogeneic HSCT, or both. The target number of patients is 1,000. To be eligible a centre should perform routing CT scanning and galatomannan (GM) testing and there must be no more than 7 days between the CT scan and GM test for each case. The study design is attached.

All eligible patients who present during a specified 12-week enrolment period will be included. As this is an observational study, no change to your usual treatment regimen is required - you will be expected to follow your local treatment protocol. Data will be collected using a secure, certified, online database. Principal data collection points are at patient enrolment, 12 weeks after enrolment, and 6 months after enrolment.

If you are interested in taking part, please complete the attached questionnaire and return it to PIMDA study administration (contact information below) by May 6th. Further information will be provided to those centres who meet the criteria. If you have any questions in the meantime, please email admin@PIMDA.eu